Hims & Hers Health, Inc. (HIMS)
| Market Cap | 13.20B |
| Revenue (ttm) | 2.01B |
| Net Income (ttm) | 193.60M |
| Shares Out | 226.02M |
| EPS (ttm) | 0.79 |
| PE Ratio | 74.04 |
| Forward PE | 80.26 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 27,414,175 |
| Open | 54.40 |
| Previous Close | 54.87 |
| Day's Range | 54.11 - 58.40 |
| 52-Week Range | 16.05 - 72.98 |
| Beta | 2.14 |
| Analysts | Hold |
| Price Target | 37.20 (-36.3%) |
| Earnings Date | Nov 3, 2025 |
About HIMS
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supp... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for HIMS stock is "Hold." The 12-month stock price target is $37.2, which is a decrease of -36.30% from the latest price.
News
Hims & Hers: Growth Meets FDA Scrutiny And Tariff Risks
Hims & Hers Health, Inc. has shown strong growth, overcoming partnership fallout and posting a 73% year-over-year revenue surge, but faces execution and regulatory risks. HIMS stock's premium valuatio...
Hims & Hers Powers YieldMax's Latest Options-Based Income ETF
YieldMax ETFs grew its expanding lineup of income-oriented funds on Tuesday with the introduction of the YieldMax HIMS Option Income Strategy ETF (NYSE: HIYY).
Berger Montague Investigates Hims & Hers Health Inc. (NYSE: HIMS) Board of Directors for Potential Breaches of Fiduciary Duties
PHILADELPHIA , Sept. 19, 2025 /PRNewswire/ -- Berger Montague , a national securities litigation law firm, advises shareholders of Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS)...
Hims & Hers Health: Bumpy Ride Will End
Hims & Hers Health has traded very volatile over the last year as the market misunderstand the business opportunity beyond GLP-1s and weight-loss drugs. The online health and wellness faces FDA scruti...
Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs
The U.S. Food and Drug Administration's recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question.
Trump Drug Ad Crackdown: FDA Warns Novo Nordisk, Eli Lilly, Hims
The Food and Drug Administration sent warning letters to dozens of drug companies— including popular telehealth firm Hims & Hers and pharmaceutical giants Eli Lilly and Novo Nordisk— demanding they co...
FDA Warns Hims Over Ads About Compounded Weight-Loss Drugs
The Food and Drug Administration sent warning letters to dozens of drug companies this month, including popular telehealth firm Hims & Hers, demanding they correct “false or misleading claims” about s...
Hims & Hers shares drop 6% after FDA warning on semaglutide marketing claims
Hims & Hers Health Inc. (NYSE: HIMS) saw its stock fall 6% on Tuesday following the release of a warning letter from the US Food and Drug Administration (FDA) concerning marketing claims related to it...
Hims & Hers Scrutinized For Marketing Its Product As Similar To Ozempic, Wegovy
Hims & Hers Health Inc. HIMS stock is trading lower on Tuesday. The U.S. Food and Drug Administration (FDA) issued a warning letter to Hims & Hers Health, dated Sept.
US FDA warns Hims & Hers over misleading claims on diabetes, weight-loss drugs
The U.S. Food and Drug Administration has sent a warning letter to telehealth firm Hims & Hers Health regarding its compounded versions of Novo Nordisk's diabetes drug Ozempic and weight-loss treatmen...
US FDA chief says Super Bowl ad by Hims & Hers 'breached' drug promotion rules
U.S. Food and Drug Administration Commissioner Martin Makary said on Friday that Hims & Hers' Super Bowl advertisement breached federal law as it highlighted the benefits of weight-loss drugs without ...
Hims & Hers Looks Like Hyper Growth At A Reasonable Price
Hims is now a GARP stock, combining rapid revenue and subscriber growth with a lower, fair valuation after a recent selloff. The company's scalable model, product launches, and global expansion plans ...
Marius Pharmaceuticals and Hims & Hers™ Collaborate to Expand Access to KYZATREX® (testosterone undecanoate) CIII Capsules, the First FDA-Approved Oral Testosterone Therapy Offered on the Hims & Hers Platform
RALEIGH, N.C., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc. today announced a collaboration with Hims & Hers™, one of the largest digital health platforms for men, to make KYZATREX®...
Hims & Hers Bets On Hormonal Health To Revive Investor Confidence
Hims & Hers Health Inc. HIMS launched a new category in men's health on Wednesday, offering access to affordable and personalized treatment plans for low testosterone.
Hims & Hers: The Next Chapter For Investors
Revenue is scaling rapidly, from $150M in 2020 to ~$2.3B expected in 2025. Over 90% of revenue is recurring subscriptions, ensuring stability and visibility. The vertically integrated model builds a b...
Hims & Hers launches treatment plans for low testosterone
Hims & Hers Health said on Wednesday it is launching a new category in men's health, offering access to personalized treatment plans for low testosterone.
Hims Launches New Category in Men's Health with Exclusive Branded Oral Testosterone and Expanded Personalized Treatments
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the launch of a new category in men's health, offering access to innova...
Hims & Hers Health Expands Testosterone Offerings
Hims & Hers Health is launching treatments for low testosterone on its telehealth platform, venturing deeper into a category often marred by stigma, according to its chief executive.
Trump aims to curb direct-to-consumer ads for drugs. Hims & Hers Health could be targeted.
President Donald Trump's administration on Tuesday rolled out an executive action aimed at limiting direct-to-consumer advertising for pharmaceuticals, with officials saying a recent Hims & Hers Healt...
Hims & Hers Health: At The Intersection Of Secular Megatrends
Hims & Hers Health, Inc. remains a Strong Buy as it is well-positioned to capitalize on secular wellness and digital health trends favored by younger generations. The company boasts stellar fundamenta...
Hims & Hers Health: Still Undervalued
Hims & Hers is fundamentally undervalued, trading at a forecast P/S ratio of 3.5 despite strong 88% YoY growth and European expansion. Low valuation and scaling by ZAVA lead to a buy rating. Short int...
Hims & Hers: The Dominant Health Platform Of The Future
Hims & Hers is evolving into a robust health platform, showing strong subscriber growth, rising ARPU, and expanding into weight loss, hormone health, labs, and international markets. Q2 results confir...
Rocket, Oscar, Hims & Hers: Short Sellers Are Playing With Fire
Wall Street's most crowded shorts are starting to look like powder kegs. Rocket Companies Inc RKT, Oscar Health Inc OSCR, and Hims & Hers Health Inc HIMS are sitting at the top of the market's short-i...
Hims & Hers Health, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - HIMS
LOS ANGELES , Aug. 25, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims & Hers" or "the Company") (NYSE: HIMS)...
Hims & Hers (HIMS) Stock Lawsuits: Investors Urged to Act - Hagens Berman
SAN FRANCISCO, Aug. 24, 2025 (GLOBE NEWSWIRE) -- Investors who lost money in Hims & Hers (NYSE: HIMS) are being urged to actively participate in a securities class action lawsuit. The lawsuit alleges ...